COMP <GO>
IART vs ABBV // GROSS PROFIT MARGIN
Integra LifeSciences Holdings Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IART 0
— ABBV 11
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $12.83 (+4.82%) • MKT CAP: $998.2M
gross-margins
50.90%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IART VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IART | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 50.90% | 70.20% | -19.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.11% | 3.47% | -6.58 | ABBV | /fcf-yield <GO> |
| Operating Margin | -30.20% | 24.60% | -54.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -31.60% | 6.90% | -38.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 8.60% | -7.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.64 | 5.33 | -4.69 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.8 | 65.1 | -22.28 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $998.2M | $513.86B | -$512.86B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IART REV | ABBV REV | IART GROSS % | ABBV GROSS % | IART FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.64B | $61.16B | 50.9% | 70.2% | -$31.1M | $17.82B |
| FY 2024 | $1.61B | $56.33B | 54.8% | 70.0% | $25.0M | $17.83B |
| FY 2023 | $1.54B | $54.32B | — | — | $140.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IART // BETA —
ABBV // BETA 1.15